-
1
-
-
84936871442
-
The evolving role of immune checkpointe inhibitors in cancer treatment
-
Pennock G, Chow L. The evolving role of immune checkpointe inhibitors in cancer treatment. Oncologist 2015;20:1-11.
-
(2015)
Oncologist
, vol.20
, pp. 1-11
-
-
Pennock, G.1
Chow, L.2
-
2
-
-
84859153479
-
Raising the bar: The curative potential of human cancer immunotherapy
-
Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
-
(2012)
Sci Transl Med
, vol.4
, pp. 127-128
-
-
Rosenberg, S.A.1
-
3
-
-
53049088033
-
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
-
Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-8.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5610-5618
-
-
Smith, F.O.1
Downey, S.G.2
Klapper, J.A.3
Yang, J.C.4
Sherry, R.M.5
Royal, R.E.6
-
4
-
-
48249117436
-
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at thenationalcancer institute between 1986 and 2006
-
Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the Surgery Branch at theNationalCancer Institute between 1986 and 2006. Cancer 2008;113:293-301.
-
(2008)
Cancer
, vol.113
, pp. 293-301
-
-
Klapper, J.A.1
Downey, S.G.2
Smith, F.O.3
Yang, J.C.4
Hughes, M.S.5
Kammula, U.S.6
-
5
-
-
0033024863
-
Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
-
Atkins MB, Lotze MT, Dutcher JP, Fisher RI,Weiss G, Margolin K, et al. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2105-2116
-
-
Atkins, M.B.1
Lotze, M.T.2
Dutcher, J.P.3
Fisher, R.I.4
Weiss, G.5
Margolin, K.6
-
6
-
-
0032471712
-
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2-Identification of the antigens mediating response
-
Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2-Identification of the antigens mediating response. Ann Surg 1998;228:307-19.
-
(1998)
Ann Surg
, vol.228
, pp. 307-319
-
-
Rosenberg, S.A.1
Yang, J.C.2
White, D.E.3
Steinberg, S.M.4
-
7
-
-
27944505913
-
Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors
-
Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005; 310:1159-63.
-
(2005)
Science
, vol.310
, pp. 1159-1163
-
-
Wang, X.1
Rickert, M.2
Garcia, K.C.3
-
8
-
-
54349096567
-
Cytokine therapy in cancer
-
Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther 2008; 8:1495-505.
-
(2008)
Expert Opin Biol Ther
, vol.8
, pp. 1495-1505
-
-
Margolin, K.1
-
9
-
-
84857646605
-
The role of interleukin-2 during homeostasis and activation of the immune system
-
Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012;12:180-90.
-
(2012)
Nat Rev Immunol
, vol.12
, pp. 180-190
-
-
Boyman, O.1
Sprent, J.2
-
10
-
-
77749279776
-
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
-
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 4275-4280
-
-
Curran, M.A.1
Montalvo, W.2
Yagita, H.3
Allison, J.P.4
-
11
-
-
84877072174
-
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
-
Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013;25:268-76.
-
(2013)
Curr Opin Immunol
, vol.25
, pp. 268-276
-
-
Gajewski, T.F.1
Woo, S.R.2
Zha, Y.3
Spaapen, R.4
Zheng, Y.5
Corrales, L.6
-
12
-
-
61349100263
-
B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer
-
Zhou P, Zheng X, Zhang H, Liu Y, Zheng P. B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer. Clin Cancer Res 2009;15:960-70.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 960-970
-
-
Zhou, P.1
Zheng, X.2
Zhang, H.3
Liu, Y.4
Zheng, P.5
-
13
-
-
1642497640
-
Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy
-
Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 2004;20:107-18.
-
(2004)
Immunity
, vol.20
, pp. 107-118
-
-
Wang, H.Y.1
Lee, D.A.2
Peng, G.3
Guo, Z.4
Li, Y.5
Kiniwa, Y.6
-
14
-
-
20344387872
-
The structure of interleukin-2 complexed with its alpha receptor
-
RickertM,Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science 2005;308: 1477-80.
-
(2005)
Science
, vol.308
, pp. 1477-1480
-
-
Rickert, M.1
Wang, X.2
Boulanger, M.J.3
Goriatcheva, N.4
Garcia, K.C.5
-
15
-
-
0028484545
-
CTLA-4 can function as a negative regulator of T cell activation
-
Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
-
(1994)
Immunity
, vol.1
, pp. 405-413
-
-
Walunas, T.L.1
Lenschow, D.J.2
Bakker, C.Y.3
Linsley, P.S.4
Freeman, G.J.5
Green, J.M.6
-
16
-
-
84959031419
-
-
[accessed 2015 Jun 29]. Available from
-
UC10-4F10-11 (ATCC- HB-304-) culture method; 2015 [accessed 2015 Jun 29]. Available from http://www.atcc.org/Products/All/HB-304. aspx#culturemethod.
-
(2015)
UC10-4F10-11 (ATCC- HB-304-) Culture Method
-
-
-
17
-
-
33644540157
-
Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor
-
Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006;103:2788-93.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 2788-2793
-
-
Stauber, D.J.1
Debler, E.W.2
Horton, P.A.3
Smith, K.A.4
Wilson, I.A.5
-
18
-
-
0028840032
-
Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureterligated rats
-
Gibbons JA, Luo ZP, Hannon ER, Braeckman RA, Young JD. Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureterligated rats. J Pharmacol Exp Ther 1995;272:119-25.
-
(1995)
J Pharmacol Exp Ther
, vol.272
, pp. 119-125
-
-
Gibbons, J.A.1
Luo, Z.P.2
Hannon, E.R.3
Braeckman, R.A.4
Young, J.D.5
-
19
-
-
0025213977
-
Pharmacokinetics of recombinant interleukin 2 in humans
-
Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, et al. Pharmacokinetics of recombinant interleukin 2 in humans.Cancer Res 1990;50:2009-17.
-
(1990)
Cancer Res
, vol.50
, pp. 2009-2017
-
-
Konrad, M.W.1
Hemstreet, G.2
Hersh, E.M.3
Mansell, P.W.4
Mertelsmann, R.5
Kolitz, J.E.6
-
20
-
-
0029947568
-
Enhancement of antitumor immunity by CTLA-4 blockade
-
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
-
(1996)
Science
, vol.271
, pp. 1734-1736
-
-
Leach, D.R.1
Krummel, M.F.2
Allison, J.P.3
-
21
-
-
42949139835
-
Phase i study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
-
Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008;26:2034-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2034-2039
-
-
Thompson, J.A.1
Curti, B.D.2
Redman, B.G.3
Bhatia, S.4
Weber, J.S.5
Agarwala, S.S.6
-
22
-
-
0030005718
-
The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice
-
Anderson JA, Lentsch AB, Hadjiminas DJ, Miller FN, Martin AW, Nakagawa K, et al. The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice. J Clin Invest 1996;97:1952-9.
-
(1996)
J Clin Invest
, vol.97
, pp. 1952-1959
-
-
Anderson, J.A.1
Lentsch, A.B.2
Hadjiminas, D.J.3
Miller, F.N.4
Martin, A.W.5
Nakagawa, K.6
-
23
-
-
84862246130
-
Sylatron: A pegylated interferon for use inmelanoma
-
Patel JN,Walko CM. Sylatron: A pegylated interferon for use inmelanoma. Ann Pharmacother 2012;46:830-8.
-
(2012)
Ann Pharmacother
, vol.46
, pp. 830-838
-
-
Patel, J.N.1
Walko, C.M.2
-
24
-
-
33748918574
-
Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs
-
Parveen S, Sahoo SK. Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 2006;45: 965-88.
-
(2006)
Clin Pharmacokinet
, vol.45
, pp. 965-988
-
-
Parveen, S.1
Sahoo, S.K.2
-
25
-
-
55749111387
-
The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics
-
Fishburn CS. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97:4167-83.
-
(2008)
J Pharm Sci
, vol.97
, pp. 4167-4183
-
-
Fishburn, C.S.1
-
27
-
-
0033758065
-
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
-
Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol 2000;18:1197-202.
-
(2000)
Nat Biotechnol
, vol.18
, pp. 1197-1202
-
-
Shanafelt, A.B.1
Lin, Y.2
Shanafelt, M.C.3
Forte, C.P.4
Dubois-Stringfellow, N.5
Carter, C.6
-
28
-
-
34250689881
-
Phase i trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
-
Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, et al. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007;13:3312-9.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3312-3319
-
-
Margolin, K.1
Atkins, M.B.2
Dutcher, J.P.3
Ernstoff, M.S.4
Smith, J.W.5
Clark, J.I.6
-
29
-
-
77955345138
-
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
-
Krieg C, L-etourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010;107:11906-11.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 11906-11911
-
-
Krieg, C.1
L-Etourneau, S.2
Pantaleo, G.3
Boyman, O.4
-
30
-
-
79957917039
-
A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity
-
Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y,Mueller SO, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011;17:3673-85.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3673-3685
-
-
Gillies, S.D.1
Lan, Y.2
Hettmann, T.3
Brunkhorst, B.4
Sun, Y.5
Mueller, S.O.6
-
31
-
-
84862776988
-
Exploiting a natural conformational switch to engineer an interleukin-2superkine'
-
Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2superkine'. Nature 2012;484:529-33.
-
(2012)
Nature
, vol.484
, pp. 529-533
-
-
Levin, A.M.1
Bates, D.L.2
Ring, A.M.3
Krieg, C.4
Lin, J.T.5
Su, L.6
-
32
-
-
84859892358
-
Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model
-
Sundstedt A, Celander M, Eriksson E, Torngren M, Hedlund G. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model. J Immunother 2012;35:344-53.
-
(2012)
J Immunother
, vol.35
, pp. 344-353
-
-
Sundstedt, A.1
Celander, M.2
Eriksson, E.3
Torngren, M.4
Hedlund, G.5
-
33
-
-
33745851479
-
CTLA4 blockade and GMCSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
-
Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GMCSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45.
-
(2006)
J Clin Invest
, vol.116
, pp. 1935-1945
-
-
Quezada, S.A.1
Peggs, K.S.2
Curran, M.A.3
Allison, J.P.4
-
34
-
-
84886443514
-
CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients
-
Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5300-5309
-
-
Ott, P.A.1
Hodi, F.S.2
Robert, C.3
-
35
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
-
(2013)
N Engl J Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
-
36
-
-
84860898062
-
The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology
-
Hafalla JC, Claser C, Couper KN, Grau GE, Renia L, De Souza JB, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Patholog 2012;8:e1002504.
-
(2012)
PLoS Patholog
, vol.8
, pp. e1002504
-
-
Hafalla, J.C.1
Claser, C.2
Couper, K.N.3
Grau, G.E.4
Renia, L.5
De Souza, J.B.6
-
37
-
-
84879104519
-
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
-
Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73: 3591-603.
-
(2013)
Cancer Res
, vol.73
, pp. 3591-3603
-
-
Duraiswamy, J.1
Kaluza, K.M.2
Freeman, G.J.3
Coukos, G.4
|